These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1503083)

  • 1. Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders.
    Friedenberg WR; Roberts RC; David DE
    Am J Hematol; 1992 Aug; 40(4):283-9. PubMed ID: 1503083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis.
    Blann AD; Dobrotova M; Kubisz P; McCollum CN
    Thromb Haemost; 1995 Aug; 74(2):626-30. PubMed ID: 8584997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Endothelial cells and vascular hemostasis].
    Levin EG; Hanano M
    Nihon Rinsho; 1992 Feb; 50(2):303-6. PubMed ID: 1319512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of tissue-type plasminogen activator, plasminogen activator inhibitor and von Willebrand factor in the supernatant of endothelial cell cultures in response to the seeding of adenocarcinoma cell line HRT-18.
    Morganti M; Mittermayer C; Henze U; Carpi A; Sagripanti A
    Biomed Pharmacother; 1996; 50(8):373-5. PubMed ID: 8952858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease.
    Sultan Y; Loyer F; Venot A
    Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.
    Cancelas JA; García-Avello A; García-Frade LJ
    Thromb Res; 1994 Sep; 75(5):513-20. PubMed ID: 7992252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis.
    Fabris F; Casonato A; Grazia del Ben M; De Marco L; Girolami A
    Br J Haematol; 1986 May; 63(1):75-83. PubMed ID: 3085704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism.
    Levesque H; Borg JY; Cailleux N; Vasse M; Daliphard S; Gancel A; Monconduit M; Courtois H
    Eur J Med; 1993 May; 2(5):287-8. PubMed ID: 8252160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease.
    Wieczorek I; Ludlam CA; MacGregor IR
    Blood Coagul Fibrinolysis; 1994 Jun; 5(3):329-34. PubMed ID: 8075304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ca2+ -regulated secretion of tissue-type plasminogen activator and von Willebrand factor in human endothelial cells.
    Knop M; Gerke V
    Biochim Biophys Acta; 2002 Nov; 1600(1-2):162-7. PubMed ID: 12445472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease.
    Ozoran K; Dügün N; Gürler A; Tutkak H; Tokgöz G
    Scand J Rheumatol; 1995; 24(6):376-82. PubMed ID: 8610223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis.
    Lau CS; McLaren M; Hanslip J; Kerr M; Belch JJ
    Ann Rheum Dis; 1993 Sep; 52(9):643-9. PubMed ID: 8239758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, t-PA and vWF.
    Bellucci S; Ignatova E; Jaillet N; Boffa MC
    Thromb Haemost; 1993 Nov; 70(5):736-42. PubMed ID: 8128427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian variation of endothelial cell function, red blood cell deformability and dehydro-thromboxane B2 in healthy volunteers.
    Bridges AB; McLaren M; Saniabadi A; Fisher TC; Belch JJ
    Blood Coagul Fibrinolysis; 1991 Jun; 2(3):447-52. PubMed ID: 1932530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes.
    Leurs PB; Stolk RP; Hamulyak K; Van Oerle R; Grobbee DE; Wolffenbuttel BH
    Diabetes Care; 2002 Aug; 25(8):1340-5. PubMed ID: 12145232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients.
    Iorio A; Federici MO; Mourvaki E; Ferolla P; Piroddi M; Stabile A; Timi A; Celleno R; Benedetti MM
    Thromb Haemost; 2007 Sep; 98(3):635-41. PubMed ID: 17849053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial marker proteins in hyperhomocysteinemia.
    de Jong SC; Stehouwer CD; van den Berg M; Vischer UM; Rauwerda JA; Emeis JJ
    Thromb Haemost; 1997 Nov; 78(5):1332-7. PubMed ID: 9408014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
    Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
    Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial haemostatic factors are associated with progression of urinary albumin excretion in clinically healthy subjects: a 4-year prospective study.
    Clausen P; Feldt-Rasmussen B; Jensen G; Jensen JS
    Clin Sci (Lond); 1999 Jul; 97(1):37-43. PubMed ID: 10369792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.